Compare MFM & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFM | CDXS |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.3M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | MFM | CDXS |
|---|---|---|
| Price | $5.33 | $2.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 125.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | $177.50 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $5.03 | $0.96 |
| 52 Week High | $5.67 | $3.87 |
| Indicator | MFM | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 50.12 |
| Support Level | $5.23 | $2.40 |
| Resistance Level | $5.48 | $2.67 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 14.29 | 21.43 |
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.